Cargando…

High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens

Mutations in the BRAF gene at or near the p. V600 locus are informative for therapy selection, but current methods for analyzing FFPE tissue DNA generally have a limit of detection of 5% variant allele frequency (VAF), or are limited to the single variant (V600E). These can result in false negatives...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Lauren Y., Haydu, Lauren E., Song, Ping, Nie, Jianyi, Tetzlaff, Michael T., Kwong, Lawrence N., Gershenwald, Jeffrey E., Davies, Michael A., Zhang, David Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079675/ https://www.ncbi.nlm.nih.gov/pubmed/33907234 http://dx.doi.org/10.1038/s41598-021-88391-5

Ejemplares similares

Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen(®) FFPE BRAF qPCR assay
por: Sørensen, Anna Lahn, et al.
Publicado: (2023)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
por: Fischer, Grant M., et al.
Publicado: (2020)

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma
por: Siroy, Alan E., et al.
Publicado: (2014)

Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens
por: Buxhofer-Ausch, Veronika, et al.
Publicado: (2013)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens
por: Dressler, Franz F., et al.
Publicado: (2022)

SDPS-37 IDENTIFICATION OF TIME-COURSE RELATED, TREATMENT-RELATED, AND PATIENT-RELATED PROGNOSTIC FACTORS IN BRAF-MUTANT MELANOMA BRAIN METASTASES.
por: Erickson, Lily G, et al.
Publicado: (2023)

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma
por: White, Michael G., et al.
Publicado: (2021)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

SimFFPE and FilterFFPE: improving structural variant calling in FFPE samples
por: Wei, Lanying, et al.
Publicado: (2021)

Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma
por: Menzies, Alexander M., et al.
Publicado: (2014)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR
por: Gao, Jie, et al.
Publicado: (2016)

SangeR: the high-throughput Sanger sequencing analysis pipeline
por: Schmid, Kai, et al.
Publicado: (2022)

Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial
por: Kapp, Joshua R, et al.
Publicado: (2015)

Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma
por: Tawbi, Hussein, et al.
Publicado: (2022)

NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
por: Flockhart, R J, et al.
Publicado: (2009)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
por: Zhang, Simeng, et al.
Publicado: (2023)

qSanger: Quantification of Genetic Variants in Bacterial Cultures by Sanger Sequencing
por: Prakash, Satya, et al.
Publicado: (2023)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

Digital multiplexed analysis of circular RNAs in FFPE and fresh non‐small cell lung cancer specimens
por: Pedraz‐Valdunciel, Carlos, et al.
Publicado: (2022)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing
por: Marchant, Julie, et al.
Publicado: (2014)

Genetic Testing Requires NGS and Sanger Methodologies
por: Jennings, Lawrence J., et al.
Publicado: (2016)

Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
por: Fischer, Grant M, et al.
Publicado: (2021)

Robert M. Sanger
Publicado: (1911)

Professor Max Sänger
Publicado: (1903)

Sänger’s Cæsarean Operation
Publicado: (1886)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens
por: Frouin, Eric, et al.
Publicado: (2016)

EHPnet: Wellcome Trust Sanger Institute
por: Dooley, Erin E.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1dkk5bbosjd4u47unddr85bafj